Shares of Sage Therapeutics (SAGE) - Get SAGE Therapeutics, Inc. Report rose 3.4% to $67 in premarket trading on Friday. According to StreetInsider, Goldman Sachs has upped its price target on the stock to $103 from $65 and maintained its buy rating. Cambridge, Mass.-based Sage focuses on developing medicines to treat central nervous system disorders.
Meanwhile, Depomed (DEPO) shares were up 2.3% to $13.12. The Newark, Calif.-based company on Tuesday announced a cooperation agreement with activist investor Starboard Value. Depomed named a new CEO and three directors to the board.